Eli Lilly and Company (NYSE:LLY) Shares Bought by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 5.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 44,293 shares of the company’s stock after acquiring an additional 2,171 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Eli Lilly and Company were worth $25,819,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Lipe & Dalton purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $26,000. Thompson Investment Management Inc. purchased a new position in shares of Eli Lilly and Company during the 3rd quarter valued at about $27,000. Legacy Financial Group LLC purchased a new position in shares of Eli Lilly and Company during the 3rd quarter valued at about $35,000. Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company during the 3rd quarter valued at about $36,000. Finally, Family CFO Inc purchased a new position in shares of Eli Lilly and Company during the 3rd quarter valued at about $40,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.13% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Bank of America lifted their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research note on Wednesday, February 21st. Cantor Fitzgerald restated an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a research note on Monday, April 15th. Finally, TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded down $13.49 on Wednesday, hitting $732.20. 2,052,626 shares of the company were exchanged, compared to its average volume of 3,038,542. The stock has a market capitalization of $695.71 billion, a price-to-earnings ratio of 126.24, a price-to-earnings-growth ratio of 1.59 and a beta of 0.34. The company has a 50-day moving average price of $763.40 and a 200 day moving average price of $664.52. Eli Lilly and Company has a 1-year low of $370.68 and a 1-year high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.09 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.